Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has secured $2.5 million in gross proceeds through warrant exercises. The company entered agreements with certain warrant holders to exercise warrants for 1,477,596 shares at a reduced price of $1.723 per share.

In exchange for the immediate exercise, Autonomix will issue new unregistered warrants for an equivalent number of shares, exercisable at $1.723 per share with a five-and-a-half-year term. Some holders opted to prepay $1.722 of the exercise price, receiving amended warrants with a $0.001 exercise price. The transaction is expected to close around July 23, 2025.

Positive

• None.

Negative

• Reduced warrant exercise price indicates potential dilution at below-market rates
• Additional dilution potential from new warrant issuance
• New warrants are unregistered, requiring additional registration statement

Insights

Financial Analyst

Autonomix secured $2.5M through warrant exercises at discounted rates, providing needed capital but with potential future dilution for shareholders.

Autonomix Medical has orchestrated a $2.5 million capital raise through the early exercise of warrants at a reduced price of $1.723 per share, down from their original price. This transaction involves 1,477,596 warrant shares originally issued in November 2024.

The structure of this deal is particularly revealing. Warrant holders are receiving new replacement warrants at the same $1.723 exercise price with a 5.5-year term, essentially giving them a second chance to benefit from any future price appreciation while providing the company with immediate capital. Some holders opted for a $1.722 prepayment with a nominal $0.001 exercise price remaining, an unusual structure that essentially guarantees their future conversion.

This financing indicates Autonomix likely needed immediate capital for operations, as they're incentivizing early warrant exercise through price reductions and replacement warrants. While securing $2.5 million improves their immediate cash position, the transaction creates potential future dilution through the new warrants, effectively doubling the potential dilutive impact. The stated use of proceeds for "working capital and general corporate purposes" without specific development milestones suggests this capital may be addressing operational needs rather than funding specific growth initiatives.

Ladenburg Thalmann's involvement as placement agent provides institutional credibility, though their fees will reduce the net proceeds below the $2.5 million gross figure. Overall, while providing necessary capital, this transaction signals potential ongoing financing challenges for Autonomix.

THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise (or prepayment of the exercise price) of certain outstanding warrants to purchase up to an aggregate of 1,477,596 shares of common stock of the Company originally issued in November 2024 at a reduced exercise price of $1.723 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282940). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.5 million, before deducting placement agent fees.

Ladenburg Thalmann & Co. Inc. is acting as the Company’s placement agent for this transaction.

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 1,477,596 shares of common stock, at an exercise price of $1.723 per share and will be immediately exercisable upon issuance and for a term of five and one-half years from the issuance date. In lieu of a complete exercise of the warrants described above, certain warrant holders agreed to prepay $1.722 of the reduced exercise price and will receive an amended warrant for such prepaid portion of the warrant with an exercise price of $0.001 per share.

The transaction is expected to close on or about July 23, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the closing of the warrant exercise transaction and the use of the proceeds thereof. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com

FAQ

How much funding did Autonomix Medical (AMIX) raise through warrant exercises in July 2025?

Autonomix Medical raised $2.5 million in gross proceeds through the exercise of warrants at a reduced price of $1.723 per share.

What is the exercise price for AMIX's new warrants issued in July 2025?

The new unregistered warrants have an exercise price of $1.723 per share and will be exercisable for up to 1,477,596 shares of common stock.

How long is the term for Autonomix Medical's new warrants issued in July 2025?

The new warrants have a term of five and one-half years from their issuance date and are immediately exercisable.

How will Autonomix Medical (AMIX) use the proceeds from the warrant exercise?

Autonomix Medical intends to use the net proceeds for working capital and general corporate purposes.

Who is the placement agent for AMIX's warrant exercise transaction?

Ladenburg Thalmann & Co. Inc. is acting as the placement agent for this transaction.